Please try another search
InDex Pharmaceuticals Holding AB (publ), a pharmaceutical development company, develops pharmaceutical products for patients with ulcerative colitis. The company’s lead drug candidate is Cobitolimod, which is in phase III clinical development for the treatment of patients with moderate to severe ulcerative colitis. It also develops a portfolio of other DNA based immunomodulatory sequences for the treatment of various immunological diseases. InDex Pharmaceuticals Holding AB (publ) was founded in 2000 and is headquartered in Solna, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Jonas Halfvarson | - | - | Member of Advisory Board - Europe |
Wenche Rolfsen | 71 | 2011 | Independent Chairman |
Raja Atreya | - | - | Member of Advisory Board - Europe |
Uli Hacksell | 73 | 2016 | Independent Director |
Laurent Peyrin-Biroulet | - | 2022 | Chairman of Advisory Board - Europe |
David T. Rubin | - | - | Member of Advisory Board - North America |
Walter Reinisch | - | - | Member of Advisory Board - Europe |
Franco Scaldaferri | - | - | Member of Advisory Board - Europe |
Lennart Hansson | 67 | 2011 | Independent Director |
Geert D’Haens | - | - | Member of Advisory Board - Europe |
Marlene Forsell | 47 | 2020 | Independent Director |
Florian Rieder | - | - | Member of Advisory Board - North America |
Brian Gordon Feagan | - | - | Member of Advisory Board - North America |
Anna-Kaija Gronblad | 55 | 2022 | Independent Director |
Bruce E. Sands | - | - | Member of Advisory Board - North America |
Karin Bernadotte | 60 | 2022 | Independent Director |
Christina Ha | - | - | Member of Advisory Board - North America |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review